NCT07073534View on ClinicalTrials.gov

Phase I/II Clinical Study of SHR-1501 Combined With Adbelizumab in Patients With Malignant Tumors

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

203

Participants

Timeline

Start Date

July 31, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
Patients With Advanced or Metastatic Malignant Tumors
Interventions
DRUG

SHR-1501, Adebrelimab

the combination of SHR-1501 and Adebrelimab

Trial Locations (1)

510000

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors
lead

Shanghai Hengrui Pharmaceutical Co., Ltd.

INDUSTRY

NCT07073534 - Phase I/II Clinical Study of SHR-1501 Combined With Adbelizumab in Patients With Malignant Tumors | Biotech Hunter | Biotech Hunter